Nisa Investment Advisors, LLC Cel Sci Corp Transaction History

Nisa Investment Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 25, 2021	BUY	$11.05 - $16.62 $1,657 - $2,493	150 Added 32.97%	605 $7,000
Q2 2020 Jul 27, 2020	SELL	$9.75 - $17.6 $48 - $88	-5 Reduced 1.09%	455 $7,000
Q1 2020 Apr 17, 2020	BUY	$7.54 - $17.05 $3,468 - $7,843	460 New	460 $5,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.